|
| |
Image Results
Loading...
Loading...
REMICADE Pages on BioPortfolio:
|
BioPortfolio - Decision Resources - Driven by Sales of Enbrel ...
30 Apr 2009 ... Read Driven by Sales of Enbrel, Remicade and Humira, ... Remicade and Humira, spondyloarthropathies Drug Market Grew to Nearly $2 Billion in ...
http://www.bioportfolio.com/news/Driven_by_Sales_of_Enbrel,_...
|
Biotechnology News ORTHO-CEPT Search
Sales of Remicade, Humira and Simponi Will Drive the TNF-Alpha Inhibitor Drug Class to Nearly Triple by 2018 for the Treatment of Ulcerative Colitis ...
http://www.bioportfolio.co.uk/ORTHO-CEPT-news.htm...
|
Stakeholder Insight Inflammatory Bowel Disease Debate over early ...
19 Dec 2007 ... Remicade remains the first choice biologic therapy in 80% of ... However, Humira has distinct advantages over Remicade that will lead to strong. ...
http://www.bioportfolio.com/cgi-bin/acatalog/Stakeholder_Ins...
|
Biotechnology News CIMZIA Search
TNF-alpha Inhibitors, Most Notably Humira and Remicade, Will Continue to Dominate the Crohn's Disease Drug Mar Autoimmune Diseases Breaking News PRNEWSWIRE ...
http://www.bioportfolio.co.uk/CIMZIA-news.htm...
|
Biotech Tracker News - Lymphoma Risk for TNF Inhibitors
4 Mar 2003 ... We do not anticipate significant changes to our revenue models for Enbrel, Remicade, or Humira, at least until the relevant risks are better ...
http://www.bioportfolio.com/news/biotracker_74.htm...
|
Emerging treatments for inflammatory bowel disease
In 2003, Centocor's Remicade (Infliximab) became first biologic to be approved by ... Remicade is a neutralizing anti-TNF alpha antibody approved for the ...
http://www.bioportfolio.com/news/DailyUpdates_73.htm...
|
Rheumatoid Arthritis: Abbott looking for a greater share
This has opened up considerable opportunity for drugs such as Remicade and Enbrel, ... Immunex's Enbrel and Centocor's Remicade currently lead the anti-TNF ...
http://www.bioportfolio.com/news/datamonitor_34.htm...
| Results from other life science and pharmaceutical sites:
|